Review article
https://doi.org/10.20471/sept.2026.62.02.06
Comparative Evaluation of Donanemab and Lecanemab in Early Alzheimer’s Disease: A Clinical Practice-Oriented Narrative Review
Kuan Yu Chu
; School of Dentistry and Graduated Institute of Dental Science, College of Oral Medicine, National Defense Medical University, Taipei, Taiwan, Department of Health and Welfare, University of Taipei, Taipei, Taiwan
Abstract
Aim: The regulatory approval of donanemab (Kisunla) and lecanemab (Leqembi) represents a pivotal moment in Alzheimer's disease therapeutics, offering the first treatments that demonstrate meaningful clinical benefits while targeting underlying amyloid pathology. This narrative review provides a comprehensive clinical comparison of these novel anti-amyloid monoclonal antibodies to guide clinical practice decisions. Materials and Methods: This narrative review analyzes available clinical evidence on donanemab and lecanemab, focusing on treatment efficacy, amyloid clearance, safety profiles, and factors relevant to clinical implementation. Results: Both treatments demonstrate statistically significant slowing of cognitive decline in early Alzheimer's disease, with donanemab showing 35 % slowing in the low-medium tau population (CDR-SB: -1.86 vs placebo -2.42, p < 0.001, TRAILBLAZER-ALZ 2 study, 18 months) and lecanemab demonstrating 27 % slowing on clinical rating scales (CDR-SB: -1.21 vs placebo -1.66, p < 0.001, CLARITY-AD study, 18 months). Donanemab achieves greater amyloid clearance (84 % reduction at 18 months) compared with lecanemab (68 % reduction at 18 months), potentially allowing for treatment discontinuation after achieving adequate clearance. However, donanemab carries higher rates of amyloid-related imaging abnormalities (ARIA), with ARIA-E occurring in 24 % versus 12.6 % for lecanemab. Clinical implementation requires careful patient selection based on APOE ε4 status, baseline imaging findings, and tau burden assessment. Conclusion: This review presents evidence-based decision algorithms for treatment selection, comprehensive ARIA monitoring protocols, and practical implementation strategies. The choice between these therapies should be individualized considering patient-specific risk factors, infrastructure requirements, and cost-effectiveness considerations. While both represent significant therapeutic advances, their modest clinical benefits and safety considerations necessitate judicious patient selection and specialized monitoring capabilities.
Keywords
onoclonal antibodies; amyloid beta-peptides; apolipoprotein E; cognitive dysfunction
Hrčak ID:
352588
URI
Publication date:
16.10.2026.
Visits: 0 *